logo
The Tax System Modernization Program That Would Not Die

The Tax System Modernization Program That Would Not Die

Forbes31-03-2025
CANADA - 2025/01/21: In this photo illustration, the United States Internal Revenue Service (IRS) ... More logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)
Retaining old technology can sometimes work out in astonishing ways.
In 1943 the destroyer USS Laffey launched from Maine and began escorting convoys across the Atlantic the following year. After supporting the D-Day landing on Utah Beach and the bombardment at Normandy, the Laffey sailed around the world to the Pacific where it was in the battle of Ormoc Bay, the landing on Iwo Jima, and the invasion of Okinawa. Along the way it was hit by torpedoes, shells, and — off Okinawa — six kamikaze planes and four bombs.
The Laffey got patched up and went on to be part of the atomic bomb tests. In the early 1950s, the ship saw action in the Korean War. In the late 1950s, it patrolled the Mediterranean during the Suez Crisis. And finally, during the Cuban missile crisis, the Laffey was on standby to evacuate naval officers in the event of an attack on Washington. In 1975 it ended up being the last Sumner-class destroyer to be decommissioned and is now a museum ship in South Carolina, where it is appropriately nicknamed 'The Ship That Would Not Die.'
The Department of Government Efficiency is taking a look at the IRS's modernization program and operations, and it has found computer systems and contracted services that aren't quite the tax system equivalent of the Laffey.
CANADA - 2025/02/07: In this photo illustration, the Department of Government Efficiency (DOGE) logo ... More is seen displayed on a smartphone screen and Elon Musk's official profile on the X social network in the background. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)
The initial public assessment offered by Sam Corcos, the temporary DOGE senior adviser for technology and modernization at Treasury, is that the technology and contracts badly need an update. That assessment will come as no surprise to Tax Notes readers, who are keenly aware that the agency's technology modernization efforts are well intentioned but often redolent with déjà vu.
'The IRS has some pretty legacy infrastructure. It's actually very similar to what banks have been using — it's old mainframes running COBOL and assembly [language code], and the challenge is how do we migrate that to a modern system?' Corcos told Laura Ingraham on Fox News on March 20. 'Typically in industry, this takes a few years and maybe a few hundred million dollars. We're now 35 years into this program,' he said, asserting that it's also $15 billion over budget. The IRS didn't respond to a request to verify this claim by press time.
The IRS's computer systems should be able to interact with each other, but that's difficult when some of them are running older languages that don't integrate well with newer ones. Moving away from older technology gets even more challenging with time, which can result in siloed data and computational capabilities. Maintenance also becomes a challenge, as parts for older hardware — not to mention employees who know how to maintain it — grow scarce. And as history shows, turning the outdated-technology ship around is especially hard when confronted with the realities of government.
The IRS automated the tax administration system in the 1960s. According to a 1987 Government Accountability Office report, from 1960 through at least 1987 the IRS collected paper returns from taxpayers at 10 service centers around the country, compiled the information on magnetic tapes, and sent them to the National Computer Center, which maintained taxpayers' master file accounts. ('ADP Modernization: IRS' Redesign of Its Tax Administration System,' GAO/IMTEC-88-5FS (1987).) Accessing data internally wasn't always as easy as it should have been, in part because of the simultaneous, but siloed, development of computer systems for functional units within the IRS that didn't necessarily integrate with each other.
One of the more egregious examples of wheel-spinning on IT projects began in the 1980s. In 1982 the IRS launched the Tax System Redesign — an attempt to integrate automated data processing systems and make data more readily available internally — at a budgeted cost of $83.6 million. The plan was to comprehensively improve the IRS's technology by introducing up-to-date computers and telecommunications, provide faster access to taxpayer information and better link-related information, and automate manual processes.
An IRS worker checks through a pile of 1040 tax forms and compares them with her computer program as ... More she and hundreds of other IRS workers process 1986 tax forms in Philadelphia's northeast IRS Service Center.
The GAO report explains that over the years the IRS had developed systems to support specific functions, but that those systems were never integrated 'because of the design constraints of the master file processing system.' The result was that 'agency users are confronted with taxpayer account data that differ in format, content, and degree of accessibility.'
The redesign effort was plagued with difficulties as the IRS searched for a feasible approach. There were leadership changes in the IRS and Treasury that resulted in changes to the plan, internal dissension about whether the redesign strategies would support IRS mission requirements, and redirections that caused delays. ('ADP Modernization: IRS' Tax System Redesign Progress and Plans for the Future,' GAO/IMTEC-88-23BR (1988).)
By 1988, the IRS had finally approved a system redesign management plan that featured large corporate databases of information used by most of the departments, departmental databases, and systems to provide automated support for specific local offices. The goal was to implement the objectives in two phases, to be completed by 1994 and 1998.
Things didn't go quite according to plan. In 1995 the GAO observed that the IRS had already spent $2.5 billion on tax systems modernization since 1986 but that 'management and technical weaknesses must be corrected if modernization is to succeed.' The GAO added that the 'IRS does not have a comprehensive business strategy to cost-effectively reduce paper submissions, and it has not yet fully developed and put in place the requisite management, software development, and technical infrastructures necessary to successfully implement an ambitious world-class modernization effort.' In 1995 the projected total for the tax systems modernization program was $8 billion.
In 1997 the National Commission on Restructuring the IRS wrote 'A Vision for a New IRS,' in which it noted that the modernization program had failed 'because the IRS did not have a consistent long-term strategic vision to guide the project,' resulting in a lack of technology integration. The report said the agency had drafted a new modernization blueprint to create integrated databases and break down the barriers between effectively siloed functional units and their computer systems.
The Business Systems Modernization program was initiated in fiscal 1999. According to the GAO, as of February 2004, $1.7 billion had been appropriated for the program. Then-IRS Commissioner Mark Everson told Congress the same month that several parts of the program had missed deadlines and overrun their budgets and should be re-bid. (Prior coverage: Tax Notes, Feb. 16, 2004, p. 818.) Everson said there had been modernization progress but admitted that the IRS wasn't 'at best practice yet,' and that updating the master file and computer infrastructure was still problematic.
In 2006 the Treasury Inspector General for Tax Administration assessed the results of the eight years of the Business Systems Modernization program as 'mixed.' That year, the IRS switched its approach from completely replacing existing business systems to using them to accomplish the modernization process. It also decided to take over the role of systems integrator from the principal contractor.
On tax day in 2018, the IRS experienced a failure of the COBOL-based individual master file system that resulted in taxpayers being blocked from making payments and e-filing returns. (Prior coverage: Tax Notes, Apr. 23, 2018, p. 545.)
UNITED STATES - JULY 18: David Kautter, nominee to be an Assistant Secretary of the Treasury, ... More testifies during his confirmation hearing in the Senate Finance Committee on Tuesday, July 18, 2017. (Photo By Bill Clark/CQ Roll Call)
Then-acting IRS Commissioner David Kautter had the unfortunate job of testifying before the House Oversight Government Operations Subcommittee that morning. He promised to resolve the problem, and the House passed another modernization bill the same day.
Another modernization program, the Integrated Modernization Business Plan — a 'six-year road map for achieving necessary modernization of IRS systems,' according to the chief information officer — was released in 2019. (IRS, 'IRS Integrated Modernization Business Plan' (Apr. 2019).) The chief information officer's transmittal message repeated the common theme of IRS efforts: 'Our legacy computing infrastructure cannot keep pace with the desire for instantaneous data, real-time interactions, and other customer-centric services,' adding that 'the cost to operate our current technology ecosystem continues to increase.'
The Inflation Reduction Act ultimately gave the IRS approximately $57.8 billion, after Congress trimmed the $80 billion it initially allotted, to update antiquated computer systems, improve taxpayer services, and increase compliance and enforcement of high-income taxpayers and large corporations.
In an October 2024 update on modernization efforts following the IRA, TIGTA noted that 'the IRS continues to maintain some of the oldest information technology systems in the federal Government.' (TIGTA, 'Major Management Challenges Facing the IRS in 2025' (Oct. 15, 2024).) The same report said that $1.6 billion of the $4.8 billion total for business systems modernization in the IRA had been spent by June 2024, and seven of the 13 milestones for 'delivering cutting-edge technology, data, and analytics to operate more effectively' had been completed. TIGTA also pointed out that the IRS has historically run into problems implementing effective security and audit logs when introducing new technologies.
On the bright side, TIGTA reported that the IRS was working to streamline its data processes and efficiency, including by publishing an Enterprise Data Catalog powered by artificial intelligence that 'provides a comprehensive view of data assets and should enable data sets to be standardized so they can be used for efficient discovery, understanding, and lineage tracking.' The IRS also added data assets to the Enterprise Data Platform, allowing universal data access and analytics for users.
As in any organization, technology at the IRS requires regular updating, so there is some excuse for the seemingly perpetual work of IRS modernization. But actually updating the technology seems to be less of a challenge than the development and implementation of the IRS's projects.
WASHINGTON, DC - DECEMBER 10: U.S. President-elect Donald Trump's nominee to be Treasury Secretary ... More Scott Bessent arrives for a meeting with Sen. Mike Crapo (R-ID) in the Dirksen Senate Office Building on December 10, 2024 in Washington, DC. Nominees for Trump's upcoming administration are continuing to visit Capitol Hill this week, meeting with Senators to discuss their potential appointments. (Photo by)
Treasury Secretary Scott Bessent blamed 'entrenched interests' for siphoning off tax dollars through contracts. Corcos said he found the disconnect between the IRS's leadership and the IT employees surprising. 'It doesn't take a lot, just somebody who cares, to solve these problems,' he said. The IRS also has to contend with Congress, which has yanked funding for projects in the past.
Inertia is another problem, according to Corcos. He said that DOGE had found contracts that it couldn't identify the purpose of and canceled them. DOGE's website lists multiple IT-related contracts that have been terminated or partially canceled. Corcos also said that DOGE has cut projects from the IRS's modernization budget that would have increased complexity in the agency's systems. Tax Notes was unable to find publicly available contact information for DOGE to request further information about the terminated contracts.
Corcos compared the IRS's IT department to that of a typical midsize bank, which he said would have an IT staff of 100 to 200 and an operation and maintenance budget of roughly $20 million, while the IRS's IT department has 8,000 employees and a budget of $3.5 billion. The IRS's most recent Data Book shows roughly $3.5 billion in costs incurred for information services in fiscal 2023. (IRS Data Book 2023, Pub. 55-B, at 73, Table 32 (2024).) 'I don't really know why yet, but I will tell you that 80 percent of that budget goes to contractors and licenses,' he added. Corcos said that the IRS has 'a lot of budget' for IT.
Modernization projects at the IRS might be challenging, but they ought to stop bearing such a striking resemblance to the interminable Dickensian case of Jarndyce v. Jarndyce. Projects need not drag on year after year, with relatively little to show in the way of a conclusion. 'I'm actually pretty optimistic that we can solve this,' Corcos said, adding that his experience had been 'very positive' working with the IRS's IT employees to try to solve the problems that they know need to be solved, but 'they've been in this situation where their hands are tied.' He added, 'One encouraging thing is we actually have quite a lot of software talent on the ground [in the IRS], the people writing code.'
Bessent said his priorities for the IRS are collections, privacy, and customer service, and that 'none of those are being well served' by the current state of the modernization project. Protecting security and maintaining privacy has been a stumbling block for the IRS's past attempts to address aging infrastructure. Bessent also promised to bring more DOGE advisers out to do interviews so that taxpayers could 'see what's being done.' Echoing decades of reports on IRS modernization projects, Bessent expressed the hope that the agency would soon work 'better, cheaper, faster, and with more privacy.' It's a fine vision, but the real test will be whether the IRS can bring it to fruition.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Business Wire

time4 minutes ago

  • Business Wire

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. ('Alto') (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. 'We have had an exciting past few months marked by a promising addition to our pipeline with ALTO-207 and encouraging clinical data that provide further validation of our biomarker-driven approach to drug development,' said Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience. 'The robust clinical effects of pramipexole observed in the PAX-D study give us strong conviction in the therapeutic potential of ALTO-207 to become a meaningful option for patients with treatment resistant depression (TRD), and we look forward to initiating a potentially pivotal Phase 2b trial by mid-2026. We continued our diligent execution across our pipeline to enroll high-quality subjects and are looking forward to the upcoming clinical study readouts.' Dr. Etkin continued, 'The recent data from our exploratory study of ALTO-203 highlights our ability to better guide indication selection and trial design through our use of biomarkers, which we believe will drive better patient outcomes. Recent clinical readouts in cognitive impairment in schizophrenia (CIAS) further our view that this is an area of incredible unmet need. To our knowledge, ALTO-101, which previously demonstrated pro-cognitive effects, now represents the most advanced therapeutic candidate in a space with no currently approved treatments. We look forward to completing the ongoing study this year to further guide its development.' Pipeline Highlights ALTO-207: Acquired novel combination product with robust clinical validation; Phase 2b trial, designed to be a potentially pivotal study, in patients with treatment resistant depression expected to initiate by mid-2026. ALTO-207 is a fixed-dose combination of pramipexole, a dopamine D3-preferring D3/D2 agonist, approved for the treatment of Parkinson's disease with demonstrated antidepressant effect, and ondansetron, an antiemetic, selective 5-HT3 receptor antagonist. As a fixed-dose combination, ALTO-207 is designed to enable rapid titration and higher dosing by mitigating the dose-limiting adverse events typically experienced with pramipexole. ALTO-207 is being developed to address the significant unmet need for patients with TRD. The planned Phase 2b trial of ALTO-207, designed to be a potentially pivotal study, is expected to initiate by mid-2026. In May 2025, the Company acquired from Chase Therapeutics Corporation (Chase) a portfolio of potentially best-in-class dopamine agonist combination product candidates, including ALTO-207, formerly known as CTC-501. The link to the conference call replay is accessible on the Company's website and here. Prior to the acquisition by Alto, Chase completed a randomized, placebo-controlled Phase 2a clinical trial evaluating CTC-501 in 32 patients with depression. The primary endpoint was achieved in the study. Patients randomized to receive CTC-501 reached a mean dose of 4.1mg per day, with 67% of patients achieving the highest allowable dose of 5mg/day. CTC-501 was generally well tolerated in the maintenance period of the study. The clinical efficacy measures were evaluated as secondary endpoints and across measures CTC-501 demonstrated large, clinically meaningful effects. CTC-501 demonstrated statistically significant and clinically meaningful improvements from baseline compared to placebo on depression symptoms as measured by the Montgomery Åsberg Depression Rating Scale, or MADRS (LSM Δ vs. placebo at Week 8 = -8.2, p=0.025, Cohen's d=1.1). CTC-501 also demonstrated a significantly greater improvement compared to placebo on the Clinician Global Impression Scale of Severity, or CGI-S (LSM Δ vs. placebo at Week 8 = -0.76, p=0.04, Cohen's d=1.0). The acquisition of ALTO-207 was prompted by Alto's novel insights on dopamine biomarkers in TRD patients and the robust antidepressant effects of pramipexole exhibited in the PAX-D study conducted by the University of Oxford. Results, which were recently published in The Lancet Psychiatry, showed pramipexole augmentation of antidepressant treatment, at a target dose of 2.5mg, demonstrated a large (Cohen's d =0.87) reduction in symptoms relative to placebo at 12 weeks, but was associated with a high rate of adverse effects. The link to the online publication can be found here. The Company plans to collaborate with the National Health Service network, including PAX-D clinical sites for the planned Phase 2b trial of ALTO-207. ALTO-101: Enrollment is ongoing in Phase 2 POC CIAS trial; topline data expected in the second half of 2025. ALTO-101, a brain-penetrant PDE4 inhibitor designed as a novel transdermal formulation, is being developed for the treatment of CIAS. The novel formulation is designed to retain the desired brain effects shown with the oral formulation while avoiding the tolerability challenges and adverse effects known to be associated with PDE4 inhibitors. Enrollment remains ongoing in the Phase 2 POC trial in CIAS, with topline data expected in the second half of 2025. The Phase 2 POC trial consists of a dose-escalating treatment with ALTO-101 and is designed to enroll approximately 70 adult participants with schizophrenia between the ages of 21 and 55. The primary outcome in the study is the effect of ALTO-101 on theta band activity, the EEG measure shown to be most clearly associated with CIAS in replicated analyses of large schizophrenia datasets. Objective cognitive performance is also being evaluated. ALTO-300: Enrollment ongoing in Phase 2b adjunctive major depressive disorder trial; data expected in mid-2026. ALTO-300, also known as agomelatine, is an oral, small molecule designed to act as a melatonin agonist and 5-HT2C antagonist, and is being developed at 25mg as an adjunctive treatment in the United States for patients with major depressive disorder (MDD), characterized by an EEG biomarker. Agomelatine is an approved antidepressant medication in Europe and Australia, at both 25mg and 50mg, but has not been approved in the United States. In comparison to the 50mg dose of agomelatine, the 25mg dose has been shown to have equivalent antidepressant efficacy and has not been associated with reversible, low liver enzyme elevations observed with the 50mg dose. Topline data from the double-blind, placebo-controlled, randomized Phase 2b trial is expected in mid-2026. The Company expects to enroll approximately 200 biomarker positive patients for the final analysis sample. In the ongoing Phase 2b trial, patients who have had an inadequate response to their current antidepressant are randomized to receive either 25mg of ALTO-300 or placebo over a six-week treatment period. The study medication is being taken in addition to a patient's background antidepressant. The primary outcome is the change from baseline in MADRS score in patients with the EEG biomarker. In May 2025, the Company presented additional analyses at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP) Annual Meeting supporting the unique biomarker opportunity for patient stratification and reinforcing the well-established safety and tolerability profile for ALTO-300 in MDD. The most common adverse event observed in the completed Phase 2a trial of ALTO-300 was headache. Additionally, the Phase 2a and Phase 2b trials have involved monitoring for elevated liver enzymes (≥ 3 times the upper limit of normal), with the Phase 2b trial including a stopping rule for elevated liver enzymes. No liver function test (LFT) elevations ≥ 3 times the upper limit of normal were observed in the Company's 239-patient completed Phase 2a trial, and no patients have been stopped in the ongoing Phase 2b trial due to liver enzyme elevation, which remains blinded. The ALTO-300 biomarker signal likely reflects increased neural noise due to elevated 5-HT2C tone and reduced dopaminergic activity. Increasing 5-HT2C activity in a preclinical rodent model or directly depleting dopamine in a healthy human volunteer study—both the opposite mechanistic effect of ALTO-300—resulted in greater EEG irregularity, consistent with a biomarker positive profile. These data reinforce the direct link between ALTO-300 and the EEG biomarker used to identify MDD patients who are more likely to be responders to treatment. ALTO-100: Enrollment ongoing in Phase 2b bipolar depression trial; data expected in the second half of 2026. ALTO-100, a first-in-class, oral small molecule believed to work through enhancing neuroplasticity, is in development for the treatment of bipolar depression (BPD) in patients characterized by a cognitive biomarker. Enrollment in the randomized, double-blind, placebo-controlled Phase 2b trial remains ongoing with topline data expected in the second half of 2026. The Company expects to enroll approximately 200 patients with BPD. Patients will be evaluated over a six-week treatment period and the primary endpoint is the change from baseline on the MADRS in the patient population characterized by a cognitive biomarker. The completed Phase 2b trial evaluating ALTO-100 as a treatment for MDD demonstrated a clinically meaningful signal in the adjunctive subgroup and evidence of biomarker enrichment in the compliant subset of patients. These data support the ongoing Phase 2b trial of ALTO-100 as an adjunctive treatment in BPD. ALTO-203: Reported topline results from Phase 2 POC MDD trial. ALTO-203 is a novel, oral small molecule designed to uniquely act as a histamine H3 inverse agonist, designed to modulate circuits underlying cognition, wakefulness, and alertness. In June 2025, the Company announced the identification of a patient selection biomarker and positive pharmacodynamic results from its exploratory Phase 2 POC trial of ALTO-203 in MDD patients with elevated levels of anhedonia. The findings in the study replicated results from the Phase 1 study in healthy volunteers, where ALTO-203 treatment led to improvements in sustained attention and reductions in the EEG theta/beta ratio. Baseline EEG theta/beta ratio predicted attentional benefits of ALTO-203 in both the Phase 1 study and Phase 2 POC trial. Alto plans to report additional results from this exploratory study at a future medical meeting and expects to determine the next development steps for ALTO-203 following the complete analysis of the data set. Corporate Updates In August 2025, the Company appointed to its Board of Directors, Raymond Sanchez, M.D., a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. With the addition of Ray, Alto's Board has increased to six members. Upcoming Milestones and Events Near-Term Expected Milestones 2H 2025 — ALTO-101 Phase 2 POC CIAS trial topline data Mid-2026 — ALTO-300 Phase 2b MDD trial topline data Mid-2026 — ALTO-207 Phase 2b TRD trial initiation 2H 2026 — ALTO-100 Phase 2b BPD trial topline data Upcoming Conferences The Company is expected to present at the following upcoming conferences: H.C. Wainwright 27th Annual Global Investment Conference: September 8-10, 2025 Baird 2025 Global Healthcare Conference: September 10, 2025 TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit: September 17-18, 2025 Second Quarter 2025 Financial Highlights Cash Position: As of June 30, 2025 the Company had cash, cash equivalents, and restricted cash of approximately $148.1 million, compared to approximately $168.7 million in cash, cash equivalents, and restricted cash as of December 31, 2024. The Company expects its cash balance to support planned operations into 2028. R&D Expenses: Research and development expenses for the quarter ended June 30, 2025 were $13.1 million, as compared to $13.2 million for the same period in 2024. G&A Expenses: General and administrative expenses for the quarter ended June 30, 2025 were $5.6 million, as compared to $5.2 million for the same period in 2024. Net Loss: The Company incurred a net loss of $17.7 million for the quarter ended June 30, 2025, as compared to $16.0 million for the quarter ended June 30, 2024. About Alto Neuroscience Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto's Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto's clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression, and schizophrenia, and other mental health conditions. For more information, visit or follow Alto on X. Forward-Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'look forward,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Alto's expectations with regard to the potential benefits, activity, effectiveness and safety of its product candidates and Precision Psychiatry Platform ('Platform'); Alto's expectations with regard to the design and results of its research and development programs and clinical trials, including the timing of enrollment and the timing and availability of data from such trials; Alto's clinical and regulatory development plans for its product candidates, including the timing or likelihood of regulatory filings and approvals for its product candidates; Alto's business strategy, financial position, including anticipated cash runway, and the sufficiency of its financial resources to fund its operations through expected milestones; and other statements that are not historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation, progress and completion of clinical trials and clinical development of Alto's product candidates; the risk that Alto may not realize the intended benefits of its Platform; availability and timing of results from clinical trials; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that clinical trials may have unsatisfactory outcomes; the risk that Alto's projections regarding its financial position and expected cash runway are inaccurate or that its conduct of its business requires more cash than anticipated; and other important factors, any of which could cause Alto's actual results to differ from those contained in the forward-looking statements, which are described in greater detail in Alto's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') as well as in other filings Alto may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law. Availability of Information on Alto's Website Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.

NBA's Trail Blazers sold in $4 billion deal to owner of NHL's Hurricanes
NBA's Trail Blazers sold in $4 billion deal to owner of NHL's Hurricanes

New York Post

time34 minutes ago

  • New York Post

NBA's Trail Blazers sold in $4 billion deal to owner of NHL's Hurricanes

The owner of the NHL's Carolina Hurricanes can now add the NBA's Portland Trail Blazers to his portfolio. Tom Dundon agreed to purchase the Blazers from the estate of Paul G. Allen on Wednesday, according to multiple reports. The valuation of the deal is at a little more than $4 billion, per ESPN, and Dundon is leading a group that includes co-president of Blue Owl Capital Marc Zahr and co-CEO of Collective Global Sheel Tyle, who is also Portland-based. Advertisement 4 Carolina Hurricanes owner Tom Dundon during a 2019 interview. Icon Sportswire via Getty Images The Trail Blazers announced in May the team was up for sale and it had always been called for in Allen's will that the NBA franchise be sold 'at some point.' His sister, Jody Allen, had been acting as team governor since Allen's passing in 2018 from cancer. Advertisement Dundon confirmed the tentative to buy the NBA franchise with the Associated Press, but did not reveal terms of the sale. A spokesperson for the Hurricanes told The Athletic that Dundon 'is in the process of buying the Portland Trailblazers and is excited about the opportunity.' 4 A overhead general view of the NBA Cup painted court during a game between the Sacramento Kings v Portland Trail Blazers at the Moda Center. Getty Images A source told The Oregonian that the group 'is passionate about basketball and intends to keep the team in Portland, where it belongs.' Advertisement The Dundon-led group is also planning to talk with the city and state about a public-private partnership for a new arena, according to ESPN. 4 Jerami Grant #9, Dalano Banton #5, Shaedon Sharpe #17 and Robert Williams III #35 of the Portland Trail Blazers walk off the court. Getty Images Once a deal is finalized, the sale will need to be approved by the NBA board of governors. In the May announcement about the sale of the team, the estate said that the proceeds of the sale of the Trail Blazers would go to philanthropic endeavors. Advertisement 4 Former Trail Blazers owner Paul G. Allen, who died in 2016. Getty Images Allen's trust said the Seattle Seahawks, which his estate also owns, and the 25 percent stake in the MLS Seattle Sounders would not be included in the sale. The billionaire co-founder of Microsoft bought the franchise for $70 million in 1988 and died in 2018. It marks the latest multi-billion dollar sale of an NBA franchise this year, with the Celtics being sold for $6.1 billion in March and a deal for majority ownership of the Lakers pegging the team at a $10 billion valuation.

Hidden cost set to slash inheritance hopes
Hidden cost set to slash inheritance hopes

Yahoo

timean hour ago

  • Yahoo

Hidden cost set to slash inheritance hopes

Younger Australians are over-estimating their inheritance as cost-of-living and stagnant wages means they need more than older Australians will be able to give them. New data released by Colonial First State shows Australians aged between 18 and 29 expect to inherit a whopping $525,000 on average, when the family home and leftover super is factored in. These high expectations come as younger Australians look to the older generations to help secure their financial future. But a combination of rising aged care costs, changing government regulations in the space and the sheer longevity of older people means this optimism around how much they will inherit is 'misplaced.' CFS head of technical services Craig Day warned these high inheritance expectations will come 'under pressure'. 'When you think about what older Australians are staring down the barrel of including longevity and rising aged care cost, this ($525,000) expectation is going to come under a lot of pressure,' he told NewsWire. 'A lot of the assets that are earmarked to be paid out as an inheritance may in the future be needed elsewhere.' CFS says most older Australians intend to leave something behind, but many underestimate just how much they will have left. The family home, vehicles and any remaining superannuation top the list to be passed down to the kids, but investment portfolios and other property have largely been earmarked for retirement income. CFS chief executive of superannuation Kelly Power said young Australians also need the money. 'Young people are increasingly relying on the wealth of their parents or grandparents due to rising living costs, stagnant wage growth and housing pressures,' she said. 'At the same time, older generations are navigating the complexities of retirement planning. 'They want to support their families while ensuring their own financial security. Mr Day urged older and younger Australians to openly talk about their financial futures. 'It's important that young and old can discuss their expectations and plans openly. By having these conversations early, families can ensure that everyone is on the same page and can make informed decisions that align with their values and goals,' he said. 'It's why we're saying it's really important for families to have these conversations so they don't get to the point where it's oh bugger, I was expecting this much to pay off my mortgage before I started saving for my retirement but there's not much left.' Mr Day also said younger Australians should look at their retirement needs as early as possible, even though 'the realities of life' including cost of living pressures can make it harder to think long-term. 'It's never too early to start planning for retirement,' he said. 'The sooner you plan, the easier it becomes because you get the benefit of that compounding big snowball rolling and it helps you achieve your objectives sooner.' Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store